Neurons, of course, are the ultimate mediators of nervous system function and arbiters of neurologic status. Do surviving neurons in MS, nonatrophic and with intact axons, exhibit abnormalities at the molecular level, more subtle than axonal degeneration or neuronal atrophy? If so, are these abnormalities inconsequential molecular oddities or do they contribute to neuronal injury or perturb neuronal function? Among the molecules that make up neurons, ion channels are especially critical because they endow these cells with their signaling capabilities. Thus far, most studies on neuronal ion channels in demyelinating diseases have focused on their adaptive roles; restoration of impulse conduction can occur in chronically demyelinated axons as a result of the insertion of increased densities of sodium channels within the bared axon membrane. Emerging evidence, however, is also beginning to suggest that ion channels within neurons can be involved in maladaptive changes in MS.
Experimental studies in animal models of MS and molecular analysis of autopsy specimens from humans with MS have begun to raise the possibility that, in addition to demyelination and axonal degeneration, 2 distinct modes of dysregulated ion channel expression can injure neurons or interfere with neuronal signaling in MS. One abnormal mode of ion channel expression suggested by Kornek et al 1 is the ectopic distribution of calcium channels, which they suggest are up-regulated within the axon membrane in experimental allergic encephalomyelitis (EAE) and in MS. They used immunocytochemical methods to examine the distribution of the ␣ 1B pore-forming subunit of the N-type voltagegated calcium channel. Consistent with earlier reports, they observed a pattern of staining in the normal brain, which suggested the presence of substantial numbers of ␣ 1B subunits in presynaptic axon terminals (where they participate in synaptic transmission), but they observed only low levels of ␣ 1B within the plasma membrane of myelinated axons within normal white matter. In EAE and MS, they observed a different distribution of ␣ 1B immunoreactivity, which was present at higher levels in axons and axonal spheroids within demyelinating lesions, in a pattern similar to that of ␤-amyloid precursor protein (APP), a marker of acute axonal injury and possibly of impaired axonal transport. They interpret these results as indicating that ␣ 1B subunits (which in the normal brain are carried within axons by axoplasmic transport en route to the presynaptic terminal) are inserted into the demyelinated axon membrane in EAE and MS.
Since the expression of ␣ 1B was studied only at the protein level (and not at the messenger RNA [mRNA] or functional level), further studies are needed to confirm and extend these results. Nonetheless, it is worth considering the consequences of abnormal calcium channel deployment in demyelinated axons. Kornek et al 1 propose that increased intracellular calcium levels due to activity of voltage-gated calcium channels may activate calcium-dependent proteases (calpains) that can degrade important axonal proteins, 2,3 thus contributing to axonal injury. Action potentials traveling along the axon or depolarization triggered by an initial insult, such as inflammation, could act to activate these channels. Consistent with the hypothesis that calcium channel activity can contribute to axonal injury, it has been shown that the blockade of calcium channels (including subtype-specific blockade of N-type calcium channels 4 ) can protect a subpopulation of myelinated axons from axotomy-induced and anoxia-induced degeneration. 4, 5 A second type of molecular abnormality, termed transcriptional channelopathy, has been described in cerebellar Purkinje neurons and may perturb the ability of these cells to encode information in animal models of MS and in humans with MS. 6, 7 The timing of action potentials and the occurrence of complex bursts of action potentials within Purkinje cells are critical for the proper functioning of the cerebellum in motor control and motor learning. [8] [9] [10] It is well established that these aspects of Purkinje cell signaling depend in large part on current flowing through sodium channels. 11, 12 It is also now known that there are 10 different genes encoding molecularly distinct sodium channel subtypes, all sharing a common overall structural motif but with different amino acid sequences that endow them with different voltage-dependences and kinetic properties. 13 Purkinje cell firing patterns are perturbed in mouse mutants in which sodium channel expression is altered by knockout of specific sodium channel genes, 14 and these changes are responsible for cerebellar ataxia in these mutants. 15 To determine whether different subtypes of sodium channels are expressed in Purkinje cells in demyelinating disorders, Black et al 6 first studied the taiep rat, a mutant in which myelin is formed normally but subsequently degenerates owing to an abnormality of oligodendrocytes. Using in situ hybridization and immunocytochemistry with subtype-specific antibodies, they examined expression of the Na v 1.8 sodium channel, which is normally present only in spinal sensory neurons and trigeminal neurons (and is not detectable within the normal brain); earlier studies had shown that the expression of Na v 1.8 within spinal sensory neurons changes following axonal transection and in association with inflammation. Consistent with the selective expression of Na v 1.8 in primary sensory neurons, Na v 1.8 was not detected in control brains. However, there was enhanced expression of Na v 1.8 mRNA and of Na v 1.8 sodium channel protein within Purkinje cells following loss of myelin within the brains of taiep rats.
A more recent study examined the expression of the Na v 1.8 channel in the brains of mice with chronic relapsing EAE and in postmortem brain tissue from patients with secondary progressive MS who had a history of cerebellar deficits. 7 As expected, Na v 1.8 mRNA was not detectable within the cerebellum of control mice or humans without neurologic disease. In contrast, Na v 1.8 mRNA was clearly present within Purkinje cells of mice with chronicrelapsing EAE and in humans with MS ( Figure 1A , C, and E). Translation of the mRNA had occurred, since Na v 1.8 protein was also present ( Figure 1B, D, and F) . Taken together, these observations in 2 animal models of MS, and in humans with MS, show that the Na v 1.8 gene (which is normally inactive in the cerebellum) is aberrantly activated in Purkinje neurons, producing the Na v 1.8 sodium channel protein, which is not normally present in these cells.
Is the expression of Na v 1.8 in Purkinje cells functionally important? That is, are the Na v 1.8 channels functional and, if so, does their presence within Purkinje cells matter in terms of cerebellar activity? Because Na v 1.8 channels display a unique physiological signature characterized by depolarized voltage-dependence of inactivation, slow development of inactivation, and rapid recovery from inactivation, 16, 17 the expression of these channels in neurons that normally do not produce them would be predicted to perturb the firing patterns of these cells. Experimental support for the idea that Na v 1.8 channels can affect neuronal firing patterns has been provided by observations on 2 model systems. Studies on transgenic mice demonstrate that identical stimuli produce different patterns of action potentials in dorsal root ganglion cells (the cells in which Na v 1.8 is normally expressed), depending on whether Na v 1.8 channels are present or not; cells expressing Na v 1.8 generate larger action potentials and, when depolarized, produce pacemaker-like repetitive trains of impulses that are not seen in cells lacking Na v 1.8. 18 More recent studies have begun to extend this type of analysis to Purkinje cells, which under normal circumstances tend to generate complex, stereotyped bursts consisting of mul- tiple action potentials superimposed on a plateau depolarization.
14 Figure 2 shows the effects of Na v 1.8 channels on Purkinje cells in vitro, which are similar to the effects observed in dorsal root ganglion cells. 18 When Na v 1.8 sodium channels are experimentally expressed within Purkinje cells, the firing pattern changes markedly; Purkinje cells that express Na v 1.8 produce larger action potentials compared with the responses in Purkinje cells that lack Na v 1.8, and the secondary, tertiary, and subsequent action potentials that contribute to the bursts tend to be eliminated so that bursts are replaced by single-action potentials (Figure 2A and C) . The responses evoked by depolarizing stimuli are also different: Purkinje cells expressing Na v 1.8 produce pacemaker-like trains of largeamplitude action potentials that are not seen in normal cells ( Figure 2B and D) . Thus, similar to dorsal root ganglion cells, Purkinje cells in vitro produce substantially different patterns of activity as a result of the expression of Na v 1.8.
Since biopsy of cerebellar tissue is not commonly performed in MS, it will not be easy to establish whether these physiologic changes occur in humans with MS. Clinical observations, however, provide some support for this suggestion. The not uncommon clinical observation of patients with MS having cerebellar deficits on examination but without apparent cerebellar lesions in neuroimaging studies is consistent with the hypothesis that molecular changes that are too subtle to be detected by currently available imaging techniques can lead to dysfunction within the cerebellum. In addition, paroxysmal ataxia has been well described in MS. 19, 20 The temporal profile of the sudden and brief attacks and the therapeutic response to carbamazepine are not easily explained by demyelination or axonal degeneration. However, the similarity of these attacks to the paroxysmal episodes that occur in the episodic ataxias, which are associated with inherited channelopathies, is consistent with the hypothesis that they are the result of a channelopathy.
Although more research will be needed to fully define the extent and to understand the causes and physiologic consequences of molecular changes within neurons in MS, the available information on ion channels may present some new molecular targets and some new therapeutic opportunities. For example, if N-type calcium channels are involved in the degeneration of axons in MS, pharmacologic blockade of these channels might be expected to ameliorate, at least partially, the loss of axons. This hypothesis could be readily examined in animal models.
Participation of Na v 1.8 sodium channels in the production of cerebellar deficits in humans with MS, if con- firmed by additional experiments, may also provide a new therapeutic target. In principle, blockade of Na v 1.8 channels would be expected to restore normal electrogenesis in Purkinje cells, thus improving cerebellar function. Na v 1.8-specific channel blocking drugs are not yet available, but this may change since the deployment of Na v 1.8 channels within nociceptive spinal sensory neurons has made Na v 1.8 an attractive molecular target. 21 When Na v 1.8-specific blocking drugs are developed, a next step will be to examine the effect of these drugs in animal models of MS, such as EAE.
Finally, are the transcription or deployment of other subtypes of calcium or sodium channels or channels selective for other ions altered in MS, and in how many types of neurons does this occur? There is some evidence for abnormal expression of the Na v 1.2 sodium channel 22 and of potassium channels 23 in dysmyelinated axons in animal models. Axons and glial cells are intimately related in myelinated fibers, and both soluble factor-mediated and contact-mediated signaling from myelinating glial cells appear to modulate ion channel expression in axons. 24, 25 Thus, we may learn about other neuronal channels and receptors that are misexpressed in the demyelinating diseases. Far from being molecular oddities, these changes in the deployment of ion channels may be clinically important; although they do not detract from the importance of demyelination or axonal loss, they may suggest new molecular mechanisms and novel strategies for treating patients with MS and related disorders.
